Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that management will host 1x1 meetings with investors during the A.G.P. Virtual
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersArcutis Biotherapeutics (NASDAQ:ARQT) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1
CRVS, CTMX and NRXP Are Among Premarket Gainers
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersCytomX Therapeutics (NASDAQ:CTMX) stock increased by 154.6% to $4.15 during Wednesday's regular session. The market value of their outstanding shares is at $281.0 million. Cyclacel Pharmaceutic
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
Express News | Psyence Biomedical Ltd: Anticipates Enrolling First Subject in Q2 of 2024 and Expects Primary Endpoint Results to Be Available in 2025
Express News | Psyence Biomed Announces Phase Iib Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (Anzctr)
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners With Fluence and INGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Express News | Psyence Biomed Australian Subsidiary, Psyence Australia Partners With Fluence And INGENū CRO To Train Research Therapists For Phase IIb Psilocybin Trial
Psyence Biomed Partners With Fluence and INGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that its Australian subsidiary, Psyence Australia Pty Ltd. ("Psyence Australia"), has
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSalarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) sha
STEM, SOUN and GRFS Among Pre-market Losers & Stocks
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
Psyence Biomedical Gets Non-compliance Notification From Nasdaq
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the "Company") (NASDAQ:PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq
VERI, STI and VERB Among Mid-day Movers
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersBetter Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. Madrigal Pharmaceutical
COIN, MSTR and LSDI Among Pre-market Losers
No Data